Le Lézard
Classified in: Health, Science and technology
Subject: SLS

Alligator Bioscience AB Interim Report January-September 2017


STOCKHOLM, Oct. 25, 2017 /PRNewswire/ --

Three important collaborations in place. Results in November from ADC-1013 clinical phase I study.

Significant events, July-September

? Aptevo Therapeutics and Alligator Bioscience signed a co-development agreement on the bispecific antibody ALG.APV-527. Preclinical development and initial production activities for clinical trial materials for ALG.APV-527 commenced.

? The immuno-oncology collaboration with Stanford University was expanded. The aim is to predict the clinical efficacy of Alligator's pipeline candidates using biomarkers.

? A research contract was signed with Professor Ignacio Melero, MD, PhD, from the University of Navarra in Spain, for 4-1BB as a target molecule in immunotherapy and cancer therapy.

? The results of the Alligator-led Phase I clinical trial for ADC-1013/JNJ-64457107 will be presented at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November.

? Janssen's Phase I clinical trial for ADC-1013/JNJ-64457107 is ongoing with approximately 50 patients recruited to date.

Events after the end of the period

Alligator and collaboration partner Aptevo Therapeutics announced on 24 October that the tumor antigen 5T4, associated with many forms of solid tumors, is the second target for ALG.APV-527.

Financial summary

July-September

? Net sales, SEK 1.8 million (4.7).
? Operating loss, SEK 24.5 million (loss: 9.1).
? Loss for the period, SEK 25.8 million (loss: 7.5).
? Loss per share, SEK 0.36 (loss: 0.13).
? Cash and cash equivalents incl. bonds, SEK 588 million (659).

January-September

? Net sales, SEK 5.6 million (51.8).
? Operating loss, SEK 73.0 million (loss: 34.0)
? Loss for the period, SEK 76.3 million (loss: 29.0)
? Loss per share, SEK 1.07 (loss: 0.49)
? Cash flow for the period was a negative SEK 141.5 million (neg: 23.8), of which SEK 74.5 million was invested in corporate bonds.
? During the period, 1,275,000 warrants (230,000) were exercised for an equivalent number of shares.

Financial summary (Group)

2017

2016

2017

2016

2016


 

Jul-Sep

 

Jul-Sep

 

Jan-Sep

 

Jan-Sep

Jan-Dec

 

Net sales, TSEK

 

1,770

 

4,661

 

5,576

 

51,808

 

58,240

 

Operating profit/loss, TSEK

 

-24,459

 

-9,133

 

-73,032

 

-33,952

 

-56,082

 

Profit/loss for the period, TSEK 

 

-25,772

 

-7,545

 

-76,274

 

-29,008

 

-48,356

 

Cash flow for the period, TSEK

 

-25,409

 

-17,780

 

-141,479

 

-23,759

 

287,135

 

Cash and cash equivalents including bonds, TSEK

 

587,578

 

346,457

 

513,220

 

346,457

 

659,136

 

Equity ratio, %

 

97%

 

97%

 

97%

 

97%

 

96%

 

R&D costs as % of operating costs excluding impairments

 

69.3%

 

58.3%

 

69.5%

 

62.2%

 

64.3%

 

Earnings per share before dilution, SEK

 

-0.36

 

-0.13

 

-1.07

 

-0.49

 

-0.80

 

Earnings per share after dilution, SEK

 

-0.36

 

-0.13

 

-1.07

 

-0.49

 

-0.80

 

Average number of employees

 

43

 

33

 

40

 

31

31

The complete report is attached in the link below.

For further information, please contact:

Per Norlén
CEO
[email protected]
+46-46-286-42-80

Per-Olof Schrewelius
CFO
[email protected]
+46-46-286-42-85

Rein Piir
VP IR
[email protected],
+46-46-286-42-80

Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
Phone +46-46-286-42-80
www.alligatorbioscience.com

Alligator Bioscience AB (publ) is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was provided to the media, through the agency of the contact persons set out above, for publication on October 25, 2017 at 08.00 a.m. CEST.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab-interim-report-january-september-2017,c2374749

The following files are available for download:

http://mb.cision.com/Main/12681/2374749/741069.pdf

Alligator Bioscience AB Interim Report January-September 2017. The complete report.

 


These press releases may also interest you

at 12:10
The National Fire Protection Association® (NFPA®), a global self-funded nonprofit organization devoted to eliminating death, injury, property, and economic loss due to fire, electrical, and related hazards, today announced the establishment of NFPA...

at 12:05
HTEC, a global digital consulting, software engineering, and product development company, is announcing a strategic collaboration with G2 Risk Solutions (G2RS), the preeminent provider of end-to-end bankruptcy technology solutions. Under the...

at 12:05
Enterprise Connect, the leading conference and exhibition for enterprise communications and customer experience (CX), brought IT decision-makers together to improve business communications and CX. Attendees explored industry trends and technologies...

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:00
Helika, a leading global infrastructure provider for traditional and Web3 gaming, launches Helika Accelerate, an accelerator program dedicated to supporting top gaming studios around the globe to develop Web3 games and to sustain growth in users and...

at 12:00
The Russell Innovation Center for Entrepreneurs (RICE), the largest center in the world dedicated to growing, scaling, and developing Black entrepreneurs proudly announces the strategic enhancement of its leadership team with two distinguished...



News published on and distributed by: